| New and Improved? 21(st) Century Cures Act Revisions to Certificates of Confidentiality |
5 |
| Digital Manipulation of Images of Models' Appearance in Advertising: Strategies for Action Through Law and Corporate Social Responsibility Incentives to Protect Public Health |
4 |
| 21(st) Century Cures for the Opioid Crisis: Promise, Impact, and Missed Opportunities |
4 |
| Real-World Data Analytics Fit for Regulatory Decision-Making |
4 |
| Mind the Gap: Antitrust, Health Disparities and Telemedicine |
3 |
| Baby M Turns 30: The Law and Policy of Surrogate Motherhood |
2 |
| The Regulatory Failure to Define Essential Health Benefits |
2 |
| The Evolution of Federal Regulation of Human Drugs in the United States: An Historical Essay |
2 |
| Practice-Based Research Networks and the Mandate for Real-World Evidence |
2 |
| Informed Consent to Vaccination: Theoretical, Legal, and Empirical Insights |
1 |
| Fourth Amendment Protections of Health Information After Carpenter v. United States: The Devil's In The Database |
1 |
| Real-World Evidence in the Real World: Beyond the FDA |
1 |
| Federal Regulation of Infant and Toddler Food and Drink Marketing and Labeling |
1 |
| The Plenary Power Meets the Police Power: Federalism at the Intersection of Health & Immigration |
1 |
| Revisionist History? Responding to Gun Violence Under Historical Limitations |
1 |
| Is Watson for Oncology per se Unreasonably Dangerous?: Making A Case for How to Prove Products Liability Based on a Flawed Artificial Intelligence Design |
1 |
| Swaps and Chains and Vouchers, Oh My!: Evaluating How Saving More Lives Impacts the Equitable Allocation of Live Donor Kidneys |
1 |
| The Patient-to-Prisoner Pipeline: The IMD Exclusion's Adverse Impact on Mass Incarceration in United States |
1 |
| Biting the Hands that Feed the Alligators: A Case Study in Morbid Obesity Extremes, End-of-Life Care, and Prohibitions on Harming and Accelerating the End of Life |
0 |
| How the 21(st) Century Cures Act Can Mitigate the Ever Growing Problem of Mass Incarceration |
0 |
| Expansion of the Priority Review Voucher Program Under the 21st Century Cures Act: Implications for Innovation and Public Health |
0 |
| A RAT by Another Name: 21(st) Century Cures Act and Stem Cell Therapies |
0 |
| 21(st) Century Citizen Pharma: The FDA & Patient-Focused Product Development |
0 |
| The Challenge of Regulating Clinical Decision Support Software After 21(st) Century Cures |
0 |
| 21(st) Century Cures Act and Medical Device Regulation: Departure from Principles or Catching the Wave |
0 |
| Fast-Forward to the Frightening Future: How the 21(st) Century Cures Act Accelerates Technological Innovation...at Unknown Risk to Us All |
0 |
| Epilogue: Health Care, Federalism, and Democratic Values |
0 |
| Efficient Prosecution of False Claims Act Violations May Help Relieve The Current Opioid Crisis |
0 |
| Giving Voice to Medicaid: Waivers, Public Comments and Kentucky's Secret Sauce |
0 |
| The American Democratic Deficit in Assisted Reproductive Technology Innovation |
0 |
| Nobody Knew How Complicated: Constraining The President's Power To (Re)Shape Health Reform |
0 |
| Food as a Biopower Means of Control: The Use of Food in Asylum Regimes |
0 |
| Exclusive Drug Labeling Rights as a New Incentive for Contribution to a Communal Biomarker Resource |
0 |
| Filling Voice Promotion Gaps in Healthcare through a Comparative Analysis of Error Reporting and Learning Systems and Open Communication and Disclosure Policies in the United States and Germany |
0 |
| Retooling American Foodralism |
0 |
| An Ethical and Legal Analysis of Ovascience - A Publicly Traded Fertility Company and its Lead Product AUGMENT |
0 |
| Conflicts of Interest in Human Subject Research: The Insufficiency of US and International Standards |
0 |
| DNA and the Fourth Amendment: Would a Defendant Succeed on a Challenge to a Familial DNA Search? |
0 |
| The 21(st) Century Cures Potpourri: Was It Worth the Price? |
0 |
| Off-Label Marketing's Audiences: The 21(st) Century Cures Act and the Relaxation of Standards for Evidence-Based Therapeutic and Cost-Comparative Claims |
0 |
